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Since the introduction of treatment for the human immunodeficiency 
virus (HIV) epidemic through the large-scale rollout of antiretroviral 
therapy (ART), the population of people receiving therapy has 
increased dramatically.1 As a result, it is becoming increasingly 
difficult and expensive to collect and collate data from individual 
patients in order to compile reports of patient entry and outcomes 
for insight into rollout programme success.2,3 The need for continued 
improvement in monitoring and evaluation (M&E) systems was 
again highlighted in the National Strategic Plan for HIV and AIDS, 
STIs and TB, 2012 - 2016 (NSP).4 Furthermore, the critical role of 
integrating M&E with electronic systems has been emphasised by the 
World Health Organization (WHO).5
ART drugs are highly effective at suppressing HIV in humans, as 
demonstrated by randomised controlled clinical trials.6 However, 
the controlled environment within trials is very different from 
the clinical setting where the impact of ART on a population 
is determined primarily by programmatic issues of treatment 
availability, accessibility and delivery.7 An innovative approach to 
monitoring ART programmes is required that is simple and efficient, 
and provides results that can be reliably interpreted, in settings such 
as South Africa (SA), where drug delivery occurs in an overburdened 
health system to sick, frequently impoverished individuals and 
adherence to treatment regimens cannot be assumed. 
Extensive use is made of remote sensing in the earth and biological 
sciences, when the spatial scale of the investigation is too large to 
be done at ground level on individual plants or geographical units.8 
Essentially an image is taken of the landscape from a distance and the 
information contained in the image is analysed in order to interpret 
patterns that are present. In these examples, technology is used to 
assess the health of forests and other landscapes, monitor nutrient 
levels in standing farm crops and identify early outbreaks of disease.8  
This information is then used to target specific interventions. 
Currently routine laboratory tests are seen as a necessary expense 
in individual patient care.9 The records are stored in the individual’s 
clinical notes but also, importantly, in centralised databases 
maintained by clinical laboratory services. The aim of this study was 
to demonstrate an analogous process of remote sensing by making 
use of a large, well-collected data set to illustrate the tremendous 
density of stored information that can be used to gain valuable 
insights into programme performance and population responses to 
ARV treatment.
Methods
This was a retrospective cohort study of patients within a SA non-
government organisation (NGO)-run clinic system for the period 
January 2004 to June 2011. Nineteen data sets, representing 17 clinics 
from 5 of the 9 provinces in SA, were supplied from the Southern 
African Catholic Bishops’ Conference/Catholic Relief Services 
(SACBC/CRS) ART programme. 
Each data set consisted of 3 comma-separated variable files 
(extension .csv) containing data of laboratory tests, a main, 
anonymised, clinical and demographic data file and regimen 
information. Individual files were imported into a Microsoft 
Access database. Duplicate records, records with date errors and 
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Aims. We describe a monitoring system at population level of 
patients on antiretroviral therapy (ART) using centrally collected 
laboratory data. We demonstrate an analogous process of remote 
sensing using a large set of laboratory results and illustrate the 
tremendous density of information stored. We moved from an 
individual to a community view of ART rollout, similar to remote 
sensing used in the earth and biological sciences when the spatial 
scale of the investigation is too large to be performed at ground level.
Methods. This was a retrospective cohort study of patients from 
January 2004 to June 2011. A total of 188 759 individual laboratory 
results representing 26 445 patients were analysed for average CD4 
and viral load by year. 
Results. The data showed an increasing state of health of the 
population and allowed for hypothesis generation when the trends 
did not follow expected paths.
Conclusion. In this analysis we moved away from individual-
centred data to population-level data in order to assess ART 
programme performance. Routine patient-monitoring data had 
great utility in assessment of population health. These methods 
are useful in monitoring and evaluation and effectiveness studies 
as they are easy to collect, reliable (not requiring much human 
matching or interventions) and scalable from a single clinic 
to an entire population. The larger the sample size, the more 
reliable the results, as confounders (such as incorrectly identified 
transfers out, lost-to-follow-up patients and transfers in) would 
be removed.
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mismatched dates (e.g. patient outcome before enrolment) were 
removed, resulting in 47 107 valid patient records, 34 907 regimen 
records and 410 352 blood tests comprising 141 019 blood sample 
records. A total of 28 186 patients were recorded as having started 
ART. Approval to analyse the data was granted by the institutional 
ethics review board (RecRef 169/2007). 
HIV-positive men, women and children who were receiving ART 
and had one or more CD4 or viral load blood result were included 
in the analysis. The last viral load and CD4 prior to ART initiation 
(baseline) and all CD4 and viral load values while receiving ART 
(before the recorded outcome date) were extracted yielding a 
database of 188 759 individual laboratory results, representing 26 
445 patients. No cut-off was applied to the period of time between 
baseline sample date and ART start date. Within this analysis there 
were 960 patients whose first CD4 or viral load measurement, or 
both, was more than 6 months prior to treatment start. 
CD4 analysis
Using the patient identification number, the first CD4 result for 
each patient was ascertained, and the time to the following samples 
was calculated. These values were grouped into 6-month time 
periods to yield an average CD4 recovery for the study group. 
Each patient provides one point in each time period (depending 
on time receiving treatment). The mean CD4 for each patient in 
each year was determined. The means were then grouped into 100 
unit CD4 strata. Each year was represented as a line with the CD4 
category along the x-axis and the number of patients on the y-axis. 
Alternatively the strata were divided into the biologically relevant 
categories: 0 - 200, 200 - 350, 350 - 500 and >500 CD4 cells/mm3. 
Each calendar year was plotted as a bar with the proportion of the 
population in each CD4 category comprising the components. It 
should be noted that if a patient had been receiving treatment for 
more than 1 year, their results would appear in each of the years 
receiving treatment.
Viral load analysis
The viral load trajectory for each patient over time was determined 
by identifying the first viral load (baseline) and then grouping the 
viral loads into 6-month time periods and presenting the proportion 
of the group with viral load in the different categories: suppressed, 
with a viral load of <50, 50 - 400 and >400 copies/ml. 
The mean log10 viral load for each patient for each year was 
calculated and the proportion of the population in each of the one 
log unit categories was plotted against the calendar year. It should be 
noted that if a patient had been receiving treatment for longer than 1 
year, results would appear in each of the years of treatment.
Results
When presenting data on 
individual patient recovery, it is 
common to see curves showing 
the increase in CD4 value over 
time (Fig. 1A), confirming 
drug efficacy in people who 
are adherent to treatment. The 
error bars demonstrate diversity 
in recovery, with treatment 
failures and non-adherence 
influencing the median CD4 
value. It should also be noted 
that there are fewer and fewer 
patients represented as one 
moves to the right of the figure.
A summary of the mean CD4 
value for each patient in each 
year, enabling an assessment of 
total clinic population health, 
is presented in Figs 2 and 3. 
In Fig. 2 the area under the 
curve represents the size of 
the treated population; health 
can be assessed by observing 
where the peak of the curve 
lies and by noting the bulge 
in later years which represents 
patients with CD4 counts >400 
cells/mm3. Categorisation of 
the mean CD4 value for each 
patient for each year into CD4 
strata yielded Fig. 3. This very 
clearly shows the improvement 
in population health and thus 
the effectiveness of ART rollout.
This analysis did not take 
patient age into account; 
Fig. 1. Patient recovery. (A) Median CD4 and interquartile range (IQR) (cells/mm3). (B) Proportions of viral load 
suppression over time showing the efficacy of the antiretroviral therapy in this clinic system.
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therefore, it could be argued that the increases seen are due to an 
influx of children into the clinics. However, Table 1 shows that the 
proportion of children (under 10 years of age) is small, and has been 
decreasing over the years, so that child data have not influenced the 
trends towards higher CD4 values.
The traditional view of the improvement in response to treatment 
of individual patient viral loads over time is shown in Fig. 1B. We 
would expect all ART-naïve patients to have had a viral load >50 
copies/ml. The conclusion here is that over the full monitoring period 
about 25% of patients are transferring into the clinics and are virally 
suppressed and currently receiving ART treatment. This is significant 
from a monitoring and evaluation perspective as this overview would 
be difficult to capture in a clinic setting. In moving away from a 
patient-centred to a community-centred view it is observed that the 
population viral suppression rate has increased dramatically over 
the 7-year study period, with over 60% of the population having an 
average viral load of <400 copies/ml in 2010 (the last complete year 
in the analysis).
Discussion
We clearly demonstrated that 
laboratory data can be used 
to view a care system from a 
distance to achieve remote 
sensing of the population’s 
health. Once data were compiled, 
a relatively simple analysis gave a 
very powerful overview of the 
population level response to ART 
which is of great importance in 
the assessment of the impact 
of public health ART rollout. 
This is very different to the 
traditionally held opinion that 
the patient folder is the primary 
source of information needed 
to assess treatment programme 
efficacy.
There are many advantages 
to using these laboratory data 
in this evaluation role: data are 
collected at a more centralised 
location (a single pathology 
laboratory servicing a region) 
and can be accessed as a 
single download as opposed to 
collating monthly, or quarterly, 
records into a continuous 
history; results are reliable as 
they are directly used in clinical 
practice and so internal quality 
controls are already in place 
to ensure consistency and 
accuracy of the testing.
Minimal change is needed 
to the existing health infra-
structure in order to implement 
this type of analysis. It can 
be started immediately and 
existing historical data allow 
for comparisons of current 
clinical systems with those of 
the past, without having to wait 
for the accumulation of new indicators. There is a minimal cost as 
all data are routinely collected; all that is needed is the time required 
for analysis. With some development, a reporting function can be 
built into existing databases to generate these results automatically. 
We report a very ‘clean’ analysis to show an ideal, well-run clinic 
situation. Unselected, real-world data are more chaotic but can still 
be analysed in this way. Not taking the patient’s ART start date 
into account resulted in a larger data set (222 901 records) but 
gave equivalent aggregate CD4 and viral load curves. These are 
not shown because the CD4 and viral load recovery trajectories of 
the complete data are not comparable with the traditional recovery 
curves (Figs 1A and 1B). The pretreatment laboratory data show an 
initial decline in CD4 after programme entry, followed by a sharp 
rise with ART initiation. Mirroring this is a steady increase in viral 
load followed by a sharp decline. These data cannot be used reliably 
because of the selection bias in this group with the CD4 threshold 
and other clinical data governing when the patients initiate ART. 
Many clinics make use of electronic pharmacy systems10 that could 
Fig. 2. Mean annual CD4 category (cells/mm3) showing increasing size of the patient population over time along with 
the improving health of the population demonstrated by the peak moving to the left along with the increasing proportion 
of the curve to the left of the peak.
Fig. 3. Mean annual CD4 (cells/mm3) divided in strata; the improving health of the population over time is seen by the 
diminishing size of the lower categories. The values in the boxes are the number of patients in the category. The 2011 
data are from January to June only.
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be linked to the laboratory data to give an accurate start date for 
the analysis.
We have performed this analysis on other data sets of different 
data quality (RW and CM, unpublished data) and have found that 
the curves seen in Fig. 2 can move ‘backwards’ with the peak in later 
sampling years at a lower CD4 value and the proportion of patients 
in higher CD4 categories becoming less. If the population size is 
still increasing, this could be attributed to the fact that the clinics are 
recruiting patients who are sicker, or that existing patients are failing 
treatment. If the population is decreasing, then the conclusion could 
be that the clinic is losing healthy patients and retaining or recruiting 
sick ones. It can be seen that these analyses allow for hypothesis 
generation that can then be investigated within the clinic or district. In 
this situation, Fig. 3 would show ‘flat’ strata with little increase in the 
proportion of patients in the higher CD4 categories over time. It is not 
possible to elucidate the individual factors that may be contributing 
to a poor performance curve (dysfunctional clinic, poor adherence, 
cultural issues, associated issues such as alcohol or drug abuse, etc.), 
but a broad-scale analysis can be made that rapidly identifies areas of 
concern to which investigations can then be directed.
The minimum requirements for this analysis are that the data are 
available in electronic format, and include sample date, sample type 
(CD4 or viral load), value, and patient identifiers to allow for per 
person analysis. The sample location would also be needed for clinic 
comparison or other spatial analyses.
Patient identifiers in the laboratory database are used to link 
records together. Although useful, they are not critical to these 
analyses; in the absence of identifiers, patients that have more than 
one test performed in a year would be double counted, and the area 
under the curve would represents the number of tests rather than 
number of patients. In our experience, linking different laboratory 
systems together is complicated, owing largely to the difficulty of 
linking patient identifiers. As a consequence, large-scale, centrally 
stored data are the most useful but do challenge the perspective of 
the current trend of devolving CD4 testing to the clinics, using point-
of-care machines to close the gap between testing and reporting, 
which prevents the loss of patients.11 Creation of a network of these 
machines would prevent loss of these data.  
ART programme success relies on its effectiveness. As previously 
shown,12,13 there is a need to assess the viability, successful implementation 
and uptake of treatment interventions in the public health setting 
following demonstration of the efficacy of a treatment in the artificial 
environment of a clinical trial or pilot study. Using the methods 
described here, it is possible for direct assessment of the impact of ART 
on the population at large. It should be kept in mind that only the ‘on 
treatment’ population is being monitored,14 but, with increased rollout, 
the size of the population pool with uncontrolled HIV not having yet 
entered the ART programme will decrease.
We have shown that population CD4 values are increasing, which will 
result in comorbid diseases such as tuberculosis15 decreasing in incidence. 
Mean population CD4 values in Africa have been summarised16 and, as 
Fig. 2 shows, the distribution remains very much lower than in the 
uninfected population in spite of ART.
That population viral load is decreasing can be used as a surrogate 
measure of the transmission rates within the community.14 For this 
reason we do not need to remove newly recruited patients as they are 
still a source of infection until they have become virally suppressed. 
The value in performing a baseline viral load measurement at 
treatment start is confirmed as this would permit health managers 
to assess the pool of virus in the community or health district for 
which they are responsible. In our analysis we calculated an average 
log10 viral load for each patient in the year and presented this as a 
distribution of values, while the community viral load (CVL) used 
the last viral load in each year.14
Monitoring the progress of a treated population is complex.2 While 
it is relatively easy to collect data on programme entry from clinic-
based records, it becomes very difficult to ascertain programme 
losses and cycling (multiple transfers in and out of clinics). With the 
widespread availability of treatment, an outcome of lost-to-follow-up is 
no longer equivalent to death.17 Transfers among clinics are becoming 
increasingly common as patients optimise their care strategy;18 this is 
complicated to monitor at a district level as assessment of an individual 
clinic’s lost-to-follow-up patients may include those ‘transferred out’ 
to a nearby clinic but unrecorded, while new patients entering a 
clinic’s programme may be unreported ‘transfer ins’.14 By looking at 
the programme entry viral load, an estimate of transferring in patients 
can be made and it is interesting that the 25.4% unrecognised transfers 
rate seen previously18 is similar to the results we have seen based on 
laboratory records. Furthermore, as this analysis is designed to take 
a regional view of a programme, provided the scale was large enough 
(health district level), individual transfers would not influence the 
population level CD4 and viral load assessments.
Indicators of a patient’s functional status are often recorded with 
ambiguity and misclassification.2 Monitoring the CD4 status reveals 
the population level of health and, by association, predicted functional 
status. There are moves to redefine indicators to achieve better evaluation 
of programme and population coverage and of programme quality 
(e.g. PEPFAR19). Our analysis provides data to assess both of these 
and we show development of new indicators that offer an overview of 
programme effectiveness at population level.
Table 1. Number of laboratory samples attributed to children aged <10 years, showing the decreasing proportion of samples over time
Year Total samples (N)
Age ≤10 years in year of 
sample (N)
Age >10 years in year of 
sample (N)
Percentage of ≤10-year-olds 
(%)
2004 1 645 164 1 481 9.97
2005 8 101 517 7 584 6.38
2006 14 472 946 13 526 6.54
2007 21 498 1 384 20 114 6.44
2008 30 306 1 641 28 665 5.41
2009 40 606 1 992 38 614 4.91
2010 52 070 2 424 49 646 4.66
Overall 168 698 9 068 159 630 5.68
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Conclusion
In this analysis we moved away from individual-centred to population-
level data in order to assess ART programme performance. We showed 
that routine patient-monitoring data had great utility in assessment of 
population health. The numbers of patients included in our analysis 
are approximately equivalent to those needing ART (40 000) within a 
typical health subdistrict of 400 000 - 500 000 residents.20
These methods are useful in monitoring and in evaluation and 
effectiveness surveys, as the data are easy to collect, reliable (not 
needing much human matching or interventions) and scalable from 
a single clinic to an entire population. Indeed, the larger the sample 
size, the more reliable the results will be as such confounders as 
incorrectly identified transfers out, lost-to-follow-up patients and 
transfers would be effectively removed.
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